Results demonstrate that XL647 is generally well tolerated and shows evidence of antitumor activity. A maximum tolerated dose has also been established.
“The number of patients with prolonged stable disease in this trial is encouraging. The initial partial response in one NSCLC patient and the prolonged disease stabilization in the other three NSCLC patients – all of whom had failed other therapies, appear to support our rationale for evaluating XL647 in a phase II trial in this indication,” said Gisela Schwab, senior vice president at Exelixis.
Investigators said the most common treatment-related adverse events seen in the XL647 clinical trial were rash, diarrhea, nausea, or fatigue.
A phase II trial of XL647 in patients with advanced non-small cell lung cancer was initiated in August 2006 and is ongoing.